Skip to main content
SpringerLink
Log in

Adjuvant Therapy of Malignant Melanoma and the Role of Sentinel Node Mapping

  • Conference paper
Lymphatic Metastasis and Sentinel Lymphonodectomy

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 157))

Abstract

Background: Controversy still exists about standard management of a primary melanoma. Over the last decades randomized phase III trials have addressed questions about the width of margin in relation to the Breslow thickness of the primary lesion, the role of prophylactic isolated limb perfusion, and the role of elective lymph node dissection. Overall these trials have demonstrated that less extensive surgery is as good as more extensive surgery. Wide excision margins, prophylactic isolated limb perfusions, or the elective lymph node dissection did not improve overall survival significantly in any of the phase III trials conducted.

Adjuvant Therapy in High Risk Melanoma: No standard systemic adjuvant therapy with confirmed impact on overall survival has been identified thus far for clinically node negative stage I–II (TxN0M0) patients after excision of the primary, nor for clinically node positive stage III (TxN1–2M0) patients after lymph node dissection for metastasic regional node involvement.

Poor Staging in the Past. One of the main problems associated with the trials assessing systemic adjuvant treatments in management of high risk primary melanoma is the fact that in general patients were poorly staged. About 25%–30% of patients with primaries thicker than 1.5 mm have micrometastatic disease in the regional lymph nodes and beyond. This population was usually submerged by the other 70%–75% of the patients with excellent prognosis, obscuring the potential benefit of the adjuvant surgical procedure (ELND) or a systemic adjuvant treatment.

Sentinel Lymph Node Mapping: Sentinel lymph node (SLN) mapping is resolving many of the inadequacies of the past and has completely changed the management of primary melanoma. As a small procedure with low morbidity it identifies that part of the population which has microscopic involvement of regional lymph nodes with greater precision than an elective lymph node dissection.

SLN-mapping allows for a detailed histopathologic evaluation involving multiple sections, H&E staining in combination with IHC (immunohistochemical staining) of the node with the highest chance of containing metastatic foci. Moreover in the near future it is most likely that RT-PCR on negative nodes will complete the diagnostic workup as a promising last step in the procedure to determine whether tumor cells are present in the sentinel node. Sentinel lymph node status has been shown recently to be by far the strongest independent prognostic factor of melanoma stage I–II patients. SLN-status is a much stronger prognostic factor than tumor thickness, which looses its prognostic relevance in SLN-positive patients.

Consequences for Development and/or Allocation of Adjuvant Therapy: Thus we now have a procedure by which the melanoma stage I–II population can be dissected in a group at truly high risk for recurrence and a group with truly low risk of recurrence. The high risk group with a greater than 75% chance for systemic disease can then be selected for trial participation of various systemic adjuvant therapy regimens that may be allowed to be toxic, considering the very high risk for relapse in these patients. The node negative group of patients can be selected for participation in trials evaluating systemic adjuvant treatment of low toxicity considering the low chance for distant metastatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Banzet P, Thomas A, Vuillemin E, et al: Wide versus narrow surgical excision in thin %lt;2 mm) stage I primary cutaneous malignant melanoma: long term results of a french multicentric prospective randomized trial on 319 patients. Proc. Am. Assoc. Clin. Oncol. 12:387, 1993

    Google Scholar 

  2. Ringborg U, Andersson R, Eldh J, et al: Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0mm: randomized study by the Swedish Melanoma Study Group. Cancer 77:1809–1814, 1996

    Article  PubMed  CAS  Google Scholar 

  3. Veronesi U, Cascinelli N, Adamus J, et al: Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 em [published erratum appear s in N Engl J Med 1991 Jul 25;325(4):292]. N Engl J Med 318:1159–1162, 1988

    Article  PubMed  CAS  Google Scholar 

  4. Cascinelli N: Update WHO-10 trial. WHO-program meeting, May 1995, Albany, NY, USA:317-321, 1995

    Google Scholar 

  5. Balch CM, Urist MM, Karakousis CP, et al: Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (l to 4 mm). Results of a multi-institutional randomized surgical trial [see comments]. Ann Surg 218:262–267; discussion 267-269, 1993

    Article  PubMed  CAS  Google Scholar 

  6. Karakousis CP, Balch CM, Urist MM, et al: Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 3:446–452, 1996

    Article  PubMed  CAS  Google Scholar 

  7. Heaton KM, Sussman JJ, Gershenwald JE, et al: Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol 5:322–328, 1998

    Article  PubMed  CAS  Google Scholar 

  8. Eggermont AMM. Treatment of melanoma in-transit metastasis confined to the limb. Cancer Surveys 1996; 26:335–349

    PubMed  CAS  Google Scholar 

  9. Franklin HR, Schraffordt Koops H, Oldhoff J, et al: To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thicknes s of 1.5mm or greater. J Clin Oncol 6:701–708, 1988

    PubMed  CAS  Google Scholar 

  10. Ghussen F, Nagel K, Groth W, et al: A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg 200:764–768, 1984

    Article  PubMed  CAS  Google Scholar 

  11. Fenn NJ., Horgan K, Johnson RC., et al: A randomized controlled trial of prophylactic isolated cytotoxic perfusion for poor-prognosis primary melanoma of the lower limb. Eur J Surg Oncol 23:6–9, 1997

    Article  PubMed  CAS  Google Scholar 

  12. Schraffordt Koops H, Vaglini M, Suciu S, et al: Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 16:2906–2912, 1998

    PubMed  CAS  Google Scholar 

  13. Balch CM, Soong S-J, Milton GW, Shaw HM, McGovern VJ, Murad TM, McCarthy WH, Maddox WA. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama USA, and New South Wales. Australia Ann Surg 1982; 196: 677

    Article  CAS  Google Scholar 

  14. Milton GW, Shaw HM, McCarthy WH, Pearson L, Balch CM, Soong S-J. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg 1982; 69:108

    Article  PubMed  CAS  Google Scholar 

  15. Reintgen DS., Cox EB, McCarthy KS Jr, Vollmer RT, Seigler HE Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg 1983; 198:379

    Article  PubMed  CAS  Google Scholar 

  16. Drepper H., Kohler CO, Bastian B, et al: Benefit of elective lymph node dissection in subgroups of melanoma patients. Results of a multicenter study of 3616 patients. Cancer 72:741–74, 1993

    Article  PubMed  CAS  Google Scholar 

  17. Slingluff CL., Jr., Stidham KR, Ricci WR, et al: Surgical management of regional lymph nodes in patients with melanoma. Ann Surg 219:120–130, 1994

    Article  PubMed  Google Scholar 

  18. Coates AS, Ingvar CI, Petersen-Schaefer K, et al: Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma unit from 1960 to 1991 [see comments]. J Am Coli Surg 180:402–409, 1995

    CAS  Google Scholar 

  19. Veronesi U, Adamus J, Bandiera DC, et al: Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 297:627–630, 1977

    Article  PubMed  CAS  Google Scholar 

  20. Veronesi U: Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 49:2420–2430, 1982

    Article  PubMed  CAS  Google Scholar 

  21. Sim FH.: A prospective randomized study of the efficacy of routine elective lymphadenopathy in management of malignant melanoma; preliminary results. Cancer 41:948–951, 1985

    Article  Google Scholar 

  22. Sim FH.: Lymphadenectomy in the management of stage 1 malignant melanoma: a prospective randomized study. Mayo Clin Proc 61:697–705, 1986

    Article  PubMed  CAS  Google Scholar 

  23. Balch CM., Soong SJ., Bartolucci AA., et al: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224:255–263; discussion 263-266, 1996

    Article  PubMed  CAS  Google Scholar 

  24. Morton DL, Wen D-R, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surgery 1992; 127:392-399

    Google Scholar 

  25. Albertini JJ, Cruse W, Berman C, et al. Intraoperative radiolymphoscintigraphy impoves sentinel lymph node identification for patients with melanoma. Ann Surg, 1996; 223:217–224

    Article  PubMed  CAS  Google Scholar 

  26. Thompson JF, McCarthy WH, Bosch CMJ, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res, 1995; 5:255–260

    Article  PubMed  CAS  Google Scholar 

  27. Gershenwald JE., Tscheng C-h, Thompson W, et al. Improved sentinel lymph node localization in primary melanoma patients with the use of radiolabeled colloid. Surgery, 1998; 124:203–210

    Article  PubMed  CAS  Google Scholar 

  28. Krag DN., Meijer SL., Weaver DL., et al. Minimal-access surgery for staging of melanoma. Arch Surg 1995; 130:654–658

    Article  PubMed  CAS  Google Scholar 

  29. Uren RF, Howman-Giles R, Thompson JF, et al. Lymphoscintigraphy to identify sentinel lymph nodes in patients with melanoma. Melanoma Res, 1994;4:395–399

    Article  PubMed  CAS  Google Scholar 

  30. Gershenwald JE., Colomi MI, Thompson W, Mansfield PE, Lee JE., Colome MI, Tcheng C-h, Balch CM, Reintgen DS, Ross MI. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol, 1998; 16:2253–2260

    PubMed  CAS  Google Scholar 

  31. Gershenwald JE., Thompson W, Mansfield PE., Lee JE., Colome MI., Tcheng C-h., Balch CM., Reintgen DS, Ross MI. Multi-institutional melanoma lymphatic mapping experience: value of sentinel lymph node status in 612 stage I or stage II melanoma patients. J Clin Oncol, 1999; 17:976–983

    PubMed  CAS  Google Scholar 

  32. Shivers SC., Wang X, Li W, Joseph E, Messina J, Glass LF., DeConti R, Cruse CW, Berman C, Fenske NA, Lyman GH, Reintgen DS. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998; 28(16)1410–1415

    Article  Google Scholar 

  33. Hill GJ. II, Moss SE., Golomb FM..., et al. DTIC and combination therapy for melanoma. Cancer 1981; 47:2556–2562

    Article  PubMed  Google Scholar 

  34. Pinsky CM., Oettgen HF.: Surgical adjuvant for malignant melanoma. Surg Clin North Am 1981; 61:1259–1266

    PubMed  CAS  Google Scholar 

  35. Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982; 307:913–916

    Article  PubMed  CAS  Google Scholar 

  36. Quirt IC., DeBoer G, Kersey PA, et al. Randomized controlled trial of adjuvant chernoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases. Can Med Assoc J 1983; 128:929–936

    Google Scholar 

  37. Fisher RI, Terry WD, Hodes RJ, et al. Adjuvant immunotherapy or chemotherapy for malignant melanoma: Preliminary report of the National Cancer Institute randomized clinical trial. Surg Clin North Am 1981; 61:1267–1277

    PubMed  CAS  Google Scholar 

  38. Loutfi A, Shakr A, Jerry M, et al. Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. Clin Invest Med 1987; 10:325–328

    PubMed  CAS  Google Scholar 

  39. Tranum BL, Dixon D, Quagliana J, et al. Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: A Southwest Oncology Group study. Cancer Treat Rep 1987; 71:643–644

    PubMed  CAS  Google Scholar 

  40. Czarnetzki BM, Macher E, Suciu S, Thomas D, Steerenberg PA, Rümke Ph. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatement in a randomised multicentre study (EORTC PROTOCOL 18781). Eur J Cancer 1993; 29A:1237–1242

    Article  PubMed  CAS  Google Scholar 

  41. Lejeune FJ, Macher E, Kleeberg UR... et al. An Assessment of DTIC versus Levamisol and placebo in the treatment of high risk stage I patients after removal of a primary melanoma of the skin, A phase III adjuvant study. EORTC PROTOCOL 18761. Eur J Cancer Clin Oncol, 1988; 24:881–890

    Article  Google Scholar 

  42. Quirt IC, Shelley WE, Pater JL. et al. Improved survival in patients with poor prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the national cancer institute of Canada clinical trials group. J Clin Oncol 1991; 9:729–735

    PubMed  CAS  Google Scholar 

  43. Spitler LE... A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991; 9:736–740

    PubMed  CAS  Google Scholar 

  44. Karakousis CP, Didolkar MS, Lopez R..., et al. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma. Cancer Treat Rep 1979; 63:1739–1743

    PubMed  CAS  Google Scholar 

  45. Balch CM, Smalley RV, Bartolucci AA... et al. A randomized prospective trial of adjuvant C. Parvum immunotherapy in 260 patients with clinically localized melanoma (stage I): progrnostic factors analysis and preliminary results of immnotherapy. Cancer 1982:49:1079–1084

    Article  PubMed  CAS  Google Scholar 

  46. Thatcher N, Mene A, Banerjee SS..., et al. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma. Br J Surg 1986; 73:111–115

    Article  PubMed  CAS  Google Scholar 

  47. Morton DL, Holmes EC, Eilber FR..., et al. Adjuvant immunotherapy: Results of a randomized trial in patients with lymph node metastases, in Terry WD, Rosenberg SA... (eds): Immunotherapy of Human Cancer. New York, NY, Elsevier North Holland, 1982, pp 245–249

    Google Scholar 

  48. Terry WD, Hodes RJ, Rosenberg SA..., et al. Treatment of stage I and II malignant melanoma with adjuvant immunotherapy or chemotherapy: Preliminary analysis of a prospective randomized trial, in Terry WD, Rosenberg SA (eds): Immunotherapy of Human Cancer. New York, NY, Elsevier North Holland, 1982, pp 252–257

    Google Scholar 

  49. Morton DL. Adjuvant immunotherapy of malignant melanoma: Status of clinical trials at UCLA. Int J Immunother 1986; 2:31–36

    Google Scholar 

  50. Wallack MK, Sivanandham M, Balch CM..., et al. A phase III randomized, double-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995; 75:34–42

    Google Scholar 

  51. Hersey P, Coates P, Tyndall L. Is adjuvant therapy worthwhile? Melanoma Res 1997; 7(Suppl): (abstract) 78

    Article  Google Scholar 

  52. Meyskens FL, Liu PY, Tuthill RI..., et al. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Soutwest Oncology Group Study J Clin Oncol 1994; 12:2060–2065

    PubMed  Google Scholar 

  53. Meyskens FL, Kopecky KI, Taylor CW et al. Randomized trial of adjuvant human Interferon-gamma versus observation in high risk cutaneous melanoma: a Southwest Oncology Group Study. J Natl. Cancer Inst 1995;87:1710–1713

    Article  PubMed  Google Scholar 

  54. Hauschild A, Burg G, Dummer R. Prospective randomized multicenter trial on the oupatient use of subcutaneous interleukin 2 and interferon a 2b in high risk melanoma patients. Melanoma Res 1997; 7(Suppll):(abstract) 401

    Article  Google Scholar 

  55. Livingstone PO, Wong GYC, Adluri S..., et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomised trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12: 1036–44

    Google Scholar 

  56. Eggemont AMM. The Current Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: prognosis versus efficacy, toxiity and costs. Melanoma Research, 1997; 7(S2) 127–131

    Google Scholar 

  57. Pehamberger H, Soyer P, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Aubock I, Fritsch P, Kerl H, Wolff K. Adjuvant interferon a-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol, 1998; 16:1425–1429

    PubMed  CAS  Google Scholar 

  58. Grob JJ, Dreno B, Chastang C, Guillot B, Cupissol B, Souteyrand P, Sassolas B, Cesarini IP, Thivolet I, Denoeux IP, Ortonne IP, Thomas T, Beylot C, Truchetet F, Lorette G, Chemaly C, Meynadier J, Amblard P, Thyss P, Avril MF, Prigent F, Bonerandi JJ. Randomised trial of interferon a-2a as adjuvant therapy in resected primary melanoma thicker than 1.5mm without clinically detectable node metastases. The Lancet, 1998; 351: 1905–1910

    Article  CAS  Google Scholar 

  59. Creagan ET, Dalton RI, Ahmann DL, et al. Randomized surgical adjuvant clinical trial or recombinant interferon-alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13:2776–2783

    PubMed  CAS  Google Scholar 

  60. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH... Interferona2b adjuvant therapy of high-risk resected curaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7–17

    PubMed  CAS  Google Scholar 

  61. Cascinelli N: Evaluation of efficacy of adjuvant rIFNa 2 A in regional node metastases. Proc Am Soc Clin Oncol 14:410, 1995 (abstr)

    Google Scholar 

  62. Kleeberg U, Broecker EB, Chartier C, et al. EORTC 18871 adjuvant trial in high risk melanoma patients IFNa vs IFNgamma vs Iscador vs Observation. Eur J Cancer 1999: 35(S4):264(abstr)

    Google Scholar 

  63. Kirkwood JM, Ibrahim J, Sondak V, et al: Preliminary analysis of the E1690/S9111/ C9190 Intergroup Postoperative Adjuvant Trial of High-and Low-Dose IFNa1pha2b (HDI and LDI) in High-Risk Primary or Lymph Node Metastatic Melanoma. Proc Am Soc Clin Oncol 1999; 18:2072 (abstr)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Erasmus Medical Center Rotterdam, Department of Surgical Oncology, University Hospital Rotterdam—Daniel Den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA, Rotterdam, The Netherlands

    A. M. M. Eggermont

Authors
  1. A. M. M. Eggermont
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Chirurgie und chirurgische Onkologie Robert-Rössle-Klinik, Universitätsklinikum Charité, Lindenberger Weg 80, 13122, Berlin, Germany

    Peter M. Schlag

  2. Istituto Europeo di Oncologia, Via Ripamonti 435, 20141, Milano, Italy

    Umberto Veronesi MD, PhD.

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Eggermont, A.M.M. (2000). Adjuvant Therapy of Malignant Melanoma and the Role of Sentinel Node Mapping. In: Schlag, P.M., Veronesi, U. (eds) Lymphatic Metastasis and Sentinel Lymphonodectomy. Recent Results in Cancer Research, vol 157. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-57151-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57151-0_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63070-5

  • Online ISBN: 978-3-642-57151-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation